Abstract | OBJECTIVES: MATERIALS AND METHODS: We retrospectively enrolled patients with locally advanced or metastatic gastric cancer from 2011 to 2016. Patients were treated with multiple cycles of fluorouracil-based chemotherapy at Peking University First Hospital. The incidence of cardiotoxicity and patients' clinical data were obtained from hospital clinical databases and manually reviewed. RESULTS: A total of 129 patients were eligible for and were enrolled in this study. A median of 6 chemotherapy cycles were administered (range 1-18 cycles). Cardiotoxicity was observed in 38 of 129 patients (29.5%). Twelve patients (9.3%) exhibited toxicity greater than grade 2, and 2 (1.6%) patients died of cardiac toxicity. The only independent risk factor for serious cardiotoxicity identified by multivariable analysis was a history of cardiac disease (OR 4.108, 95% CI 2.778-6.074, P < 0.001). CONCLUSIONS:
|
Authors | Xuan Jin, Yu Bai, Lan Gao, Shikai Wu |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 84
Issue 3
Pg. 599-607
(09 2019)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 31203389
(Publication Type: Journal Article)
|
Chemical References |
- Oxaliplatin
- Capecitabine
- Cisplatin
- Fluorouracil
|
Topics |
- Adenocarcinoma
(drug therapy, secondary)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Capecitabine
(administration & dosage)
- Cardiotoxicity
(epidemiology, etiology, pathology)
- Cisplatin
(administration & dosage)
- Female
- Fluorouracil
(administration & dosage)
- Follow-Up Studies
- Humans
- Incidence
- Lymphatic Metastasis
- Male
- Middle Aged
- Oxaliplatin
(administration & dosage)
- Prognosis
- Retrospective Studies
- Risk Factors
- Stomach Neoplasms
(drug therapy, pathology)
- Survival Rate
|